The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC).
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Gabriele Margareta Siegler
Honoraria - Eisai; Janssen-Cilag; medizinwelten services GmbH; Roche; Shire
Research Funding - Beigene (Inst); Celgene (Inst); Isofol Medical (Inst); MOLOGEN (Inst); Novartis (Inst); Nutricia (Inst); Roche (Inst); Roche/Genentech (Inst); Sanofi (Inst); Sanofi (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Lilly
 
Enrico de Toni
Honoraria - Bristol-Myers Squibb; Falk Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche
Research Funding - ArQule (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion
 
Udo Lindig
No Relationships to Disclose
 
Jurgen Siebler
No Relationships to Disclose
 
Martin Walker
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Delcath Systems; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche